NEXT to Present Keynote Presentation on Precision Medicine

NEXT Bio-Research Service’s CMO and Laboratory Director, Dai “Dave” J. Li, MD, MSc., Ph.D., FACB to present Keynote presentation on Precision Medicine at SHIMADZU 5th Global Pharma Summit, in Singapore, November 25-27, 2015.

NEXT Bio-Research Services, LLC., a Richmond VA, based biotechnology company, announced today that Dr. Dave Li, the Company’s Chief Medical Officer and Laboratory Director will present a keynote talk at the SHIMADZU 5th Global Pharma Summit in Singapore on November 25th, 2015. The presentation is entitled “

Face Regulatory Challenges with Confidence: A Precision Medicine Perspective

Dr. Li’s talk will share his experiences and knowledge of medical device regulation from published literature that he was involved in as a medical officer at the FDA from the perspective of the new and evolving field of precision medicine. Following is an abstract of Dr. Li’s presentation, the slides from his talk will be posted on NEXT BioResearch’s website following the meeting. Face Regulatory Challenges with Confidence: a precision medicine perspective Since the Human Genome Project completed twelve years ago, we have witnessed significant technological advancements in clinical measurement with the introduction of the mass spectrometry, PCR and next generation sequencing (NGS) for clinical use, which are revolutionizing our understanding the underlying pathophysiology of the complex human illnesses such as cancer and diabetes, and interactions of the pathogenic ecosystem. Medicine is shifting from a reactive mode of treating disease to a proactive model which is predictive, preventive, personalized and participatory. President Obama’s Precision Medicine Initiative (PMI) further highlights the importance of the disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles. We are facing scientific and regulatory challenges in translational medicine working with the complex human diseases with respect to data integration, information extraction, and knowledge management. In this keynote presentation, I advocate that developmental strategies should be formulated based on a common denominator which is also the basis of all regulatory decisions of the FDA.

Dai J Li, MD, MSc, PhD, FACB Chief Medical Officer/Laboratory Director Next Bio-Research Services, LLC Richmond, VA 23238, U.S.A. dli@nextbiollc.com